{"id":100736,"date":"2026-05-29T13:37:19","date_gmt":"2026-05-29T08:07:19","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=100736"},"modified":"2026-05-29T13:37:21","modified_gmt":"2026-05-29T08:07:21","slug":"bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/","title":{"rendered":"Bal Pharma Q4 FY26 Results: Revenue, PAT, Net Profit and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p><strong><a href=\"https:\/\/univest.in\/user\/stocks\/balpharma\/bal-pharma-ltd-share-price-today\">Bal Pharma<\/a> Q4 FY26 results<\/strong> were declared on May 27, 2026. The company declared results for the quarter ended March 31, 2026. Revenue from operations was Rs 83.92 crore, +2.6% YoY from Rs 81.79 crore. Results are on a standalone basis. Bal Pharma is a leading Bulk Drugs and Pharmaceuticals company listed on Indian stock exchanges.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\">Click Here &#8211; Get Free Investment Predictions<\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Bal_Pharma_Q4_FY26_Financial_Highlights\" title=\"Bal Pharma Q4 FY26 Financial Highlights\">Bal Pharma Q4 FY26 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Bal_Pharma_Q4_FY26_Performance_Analysis\" title=\"Bal Pharma Q4 FY26 Performance Analysis\">Bal Pharma Q4 FY26 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Key_Business_Factors_in_Q4_FY26\" title=\"Key Business Factors in Q4 FY26\">Key Business Factors in Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Revenue_and_Volume_Performance\" title=\"Revenue and Volume Performance\">Revenue and Volume Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Profitability_and_Margin_Trajectory\" title=\"Profitability and Margin Trajectory\">Profitability and Margin Trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Sector_and_Macro_Backdrop\" title=\"Sector and Macro Backdrop\">Sector and Macro Backdrop<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#FY27_Outlook\" title=\"FY27 Outlook\">FY27 Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Bal_Pharma_Stock_Performance\" title=\"Bal Pharma Stock Performance\">Bal Pharma Stock Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Key_Risks\" title=\"Key Risks\">Key Risks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Input_Cost_and_Margin_Volatility\" title=\"Input Cost and Margin Volatility\">Input Cost and Margin Volatility<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Demand_and_Revenue_Slowdown_Risk\" title=\"Demand and Revenue Slowdown Risk\">Demand and Revenue Slowdown Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Regulatory_and_Competitive_Risk\" title=\"Regulatory and Competitive Risk\">Regulatory and Competitive Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Frequently_Asked_Questions_on_Bal_Pharma_Q4_FY26_Results\" title=\"Frequently Asked Questions on Bal Pharma Q4 FY26 Results\">Frequently Asked Questions on Bal Pharma Q4 FY26 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#What_is_Bal_Pharma_Q4_FY26_net_profit\" title=\"What is Bal Pharma Q4 FY26 net profit?\">What is Bal Pharma Q4 FY26 net profit?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#What_is_Bal_Pharma_Q4_FY26_revenue\" title=\"What is Bal Pharma Q4 FY26 revenue?\">What is Bal Pharma Q4 FY26 revenue?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#When_were_Bal_Pharma_Q4_FY26_results_declared\" title=\"When were Bal Pharma Q4 FY26 results declared?\">When were Bal Pharma Q4 FY26 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#What_dividend_did_Bal_Pharma_declare_for_FY26\" title=\"What dividend did Bal Pharma declare for FY26?\">What dividend did Bal Pharma declare for FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#What_is_the_FY27_outlook_for_Bal_Pharma\" title=\"What is the FY27 outlook for Bal Pharma?\">What is the FY27 outlook for Bal Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#Is_Bal_Pharma_a_good_buy_after_Q4_FY26_results\" title=\"Is Bal Pharma a good buy after Q4 FY26 results?\">Is Bal Pharma a good buy after Q4 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/bal-pharma-q4-fy26-results-revenue-rs-83-92-cr-results\/#What_sector_does_Bal_Pharma_operate_in\" title=\"What sector does Bal Pharma operate in?\">What sector does Bal Pharma operate in?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Bal_Pharma_Q4_FY26_Financial_Highlights\"><\/span><strong>Bal Pharma Q4 FY26 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26<\/th>\n<th>Q4 FY25<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<tr>\n<td><strong>Revenue from Operations (Rs Cr)<\/strong><\/td>\n<td>83.92<\/td>\n<td>81.79<\/td>\n<td>+2.6%<\/td>\n<\/tr>\n<tr>\n<td><strong>Net Profit (PAT) (Rs Cr)<\/strong><\/td>\n<td>N\/A<\/td>\n<td>N\/A<\/td>\n<td>N\/A<\/td>\n<\/tr>\n<tr>\n<td><strong>Reporting Basis<\/strong><\/td>\n<td colspan=\"3\">Standalone<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Note: Q4 FY26 Revenue Rs 83.92 Cr (+2.61% YoY). Net profit details in BSE\/NSE audited filing. Always verify from BSE\/NSE audited filings before investment decisions.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bal_Pharma_Q4_FY26_Performance_Analysis\"><\/span><strong>Bal Pharma Q4 FY26 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Bal Pharma Q4 FY26 results<\/strong> reflect performance in the January to March 2026 quarter. Revenue from operations grew to Rs 83.92 crore, +2.6% YoY during the quarter. Bal Pharma operates in the Bulk Drugs and Pharmaceuticals sector and demonstrated resilience amid India&#8217;s GDP growth above 6.5% in FY26.<\/p>\n<p>India&#8217;s macroeconomic backdrop in Q4 FY26 was characterised by sustained GDP growth, government capex of Rs 11.21 lakh crore for FY27, and the RBI&#8217;s accommodative policy stance. The Bulk Drugs and Pharmaceuticals sector benefited from these structural tailwinds during the January to March 2026 quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Q4_FY26\"><\/span><strong>Key Business Factors in Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_and_Volume_Performance\"><\/span><strong>Revenue and Volume Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue from operations in <strong>Bal Pharma Q4 FY26<\/strong> grew to Rs 83.92 crore, +2.6% YoY. Steady execution supported the revenue performance. The Bulk Drugs and Pharmaceuticals sector benefited from India&#8217;s domestic demand recovery and infrastructure push in FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Profitability_and_Margin_Trajectory\"><\/span><strong>Profitability and Margin Trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net profit details for <strong>Bal Pharma Q4 FY26<\/strong> are available in the BSE\/NSE audited filing declared May 27, 2026. Investors should refer to audited financials before making investment decisions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Sector_and_Macro_Backdrop\"><\/span><strong>Sector and Macro Backdrop<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s macro environment in Q4 FY26 was characterised by GDP growth above 6.5%, budgeted central capex of Rs 11.21 lakh crore for FY27, and the RBI&#8217;s accommodative policy stance. These factors supported business investment and consumer spending. The Bulk Drugs and Pharmaceuticals sector benefited from these structural tailwinds during the quarter ended March 31, 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No dividend was declared for Q4 FY26. The company channelled cash towards operational growth and balance sheet strength in Q4 FY26.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook\"><\/span><strong>FY27 Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following the <strong>Bal Pharma Q4 FY26 results<\/strong>, investors will focus on management guidance for FY27 covering revenue growth, margin improvement, capital allocation, and order book health. Stable Q4 FY26 execution supports a constructive FY27 outlook. India&#8217;s GDP growth trajectory, domestic demand, and sector-specific catalysts will be key drivers for Bal Pharma in FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bal_Pharma_Stock_Performance\"><\/span><strong>Bal Pharma Stock Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track live price and daily stock recommendations.<\/p>\n<p>Shares of Bal Pharma are listed on NSE and BSE. Following the Q4 FY26 results on May 27, 2026, investors should monitor post-results price action, institutional activity, and management commentary. Always consult a SEBI-registered financial advisor before investment decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks\"><\/span><strong>Key Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Input_Cost_and_Margin_Volatility\"><\/span><strong>Input Cost and Margin Volatility<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Fluctuations in raw material costs, energy prices, and logistics expenses pose margin risks for Bal Pharma in FY27. Any cost escalation without corresponding pricing power could compress margins from Q4 FY26 levels.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Demand_and_Revenue_Slowdown_Risk\"><\/span><strong>Demand and Revenue Slowdown Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any deceleration in India&#8217;s GDP growth, reduction in government capex, or weakening of private consumption could impact demand for Bal Pharma&#8217;s products and services in the Bulk Drugs and Pharmaceuticals sector in FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Regulatory_and_Competitive_Risk\"><\/span><strong>Regulatory and Competitive Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Changes in regulatory frameworks, competitive pricing pressure from domestic and global peers, and customer concentration risks are key watchpoints for Bal Pharma investors. Sustained execution against strategic priorities remains critical.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Bal Pharma Q4 FY26 results declared on May 27, 2026 showed revenue of Rs 83.92 crore, +2.6% YoY. Revenue +2.6% YoY demonstrates solid execution. The results reinforce the company&#8217;s execution capability heading into FY27. Investors should monitor management guidance, sector trends, and macroeconomic developments before making investment decisions.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all data from BSE\/NSE audited filings.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Bal_Pharma_Q4_FY26_Results\"><\/span><strong>Frequently Asked Questions on Bal Pharma Q4 FY26 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Bal_Pharma_Q4_FY26_net_profit\"><\/span><strong>What is Bal Pharma Q4 FY26 net profit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bal Pharma Q4 FY26 net profit is available in the BSE\/NSE audited filing declared May 27, 2026. Results declared May 27, 2026 on standalone basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Bal_Pharma_Q4_FY26_revenue\"><\/span><strong>What is Bal Pharma Q4 FY26 revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bal Pharma Q4 FY26 revenue was Rs 83.92 crore, +2.6% YoY. Results declared May 27, 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Bal_Pharma_Q4_FY26_results_declared\"><\/span><strong>When were Bal Pharma Q4 FY26 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bal Pharma Q4 FY26 results were declared on May 27, 2026 at the board meeting approving audited financial statements for the quarter ended March 31, 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_dividend_did_Bal_Pharma_declare_for_FY26\"><\/span><strong>What dividend did Bal Pharma declare for FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend was declared for Q4 FY26. Verify from BSE\/NSE filings for record date and payout schedule.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Bal_Pharma\"><\/span><strong>What is the FY27 outlook for Bal Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Following Bal Pharma Q4 FY26 results, management guidance on revenue growth, margin improvement, and capital allocation shapes FY27 expectations. Consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Bal_Pharma_a_good_buy_after_Q4_FY26_results\"><\/span><strong>Is Bal Pharma a good buy after Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investment in Bal Pharma requires assessment of fundamentals, valuation, sector outlook, and personal risk tolerance. This article is for educational purposes only. Consult a SEBI-registered financial advisor.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_sector_does_Bal_Pharma_operate_in\"><\/span><strong>What sector does Bal Pharma operate in?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bal Pharma operates in the Bulk Drugs and Pharmaceuticals sector. The company is listed on Indian stock exchanges and declared Q4 FY26 results on May 27, 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bal Pharma Q4 FY26 results declared May 27, 2026: Revenue Rs 83.92 Cr (+2.6% YoY). PAT in BSE filing. Bulk Drugs and Pharmaceuticals. Key highlights and analysi<\/p>\n","protected":false},"author":35,"featured_media":101436,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-100736","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1780042047:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["72"],"rank_math_title":["Bal Pharma Q4 FY26 Results: Revenue Rs 83.92 Cr, Up 2.6%"],"rank_math_description":["Bal Pharma Q4 FY26 results declared May 27, 2026: Revenue Rs 83.92 Cr (+2.6% YoY). PAT in BSE filing. Bulk Drugs and Pharmaceuticals. Key highlights and analysis"],"rank_math_focus_keyword":["Bal Pharma Q4 FY26 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_wp_old_slug":["bal-pharma-q4-fy26-revenue-rs-83-92-cr-results"],"_wp_old_date":["2026-05-28"],"_thumbnail_id":["101436"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["14309"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/05\/Bal-Pharma-Q4-FY26.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/100736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=100736"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/100736\/revisions"}],"predecessor-version":[{"id":101437,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/100736\/revisions\/101437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/101436"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=100736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=100736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=100736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}